Author pages are created from data sourced from our academic publisher partnerships and public sources.
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
Background:Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is… Expand
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small cell lung… Expand
PTEN status in advanced colorectal cancer treated with cetuximab
Background:Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by… Expand
Bcl‐2 expression on fine‐needle aspirates from primary breast carcinoma
The bcl‐2 gene encodes for a protein that is involved in cell death regulation. It frequently is expressed in breast tumors, in which it is associated with favorable prognostic factors. It has been… Expand
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
A number of different clinical characteristics and molecular markers related to epidermal growth factor receptor (EGFR) activation have been reported to singly correlate with therapeutic activity of… Expand
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
- M. Bersanelli, R. Minari, +9 authors M. Tiseo
- Journal of thoracic oncology : official…
- 1 October 2016
Abstract With the advent of third-generation epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors, such as AZD9291 and CO-1686, new mechanisms of drug resistance are emerging, like… Expand
FGFR as potential target in the treatment of squamous non small cell lung cancer.
To date therapeutic options for squamous cell lung cancer patients remain scarce because no druggable targets have been identified so far. Aberrant signaling by FGFs (fibroblast growth factors) and… Expand
Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer
A series of retrospective studies have reported that patients with human epidermal growth factor receptor 2(HER2)‐positive breast cancer are at a greater risk of central nervous system (CNS)… Expand
HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
Amplification of the HER‐2/neu oncogene has been proposed as a target for antibody‐based therapies and as a predictor of chemoresponsiveness in advanced breast carcinoma. Few studies have… Expand
Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma
SummaryFine-needle aspiration cytology has been already established as a reliable method for the diagnosis of breast cancer. Its application has been recently extended to immunocytochemical analysis… Expand